PREDIX wins FDA nod for early drug trials Boston Business Journal - Boston,MA,USA of Woburn has won FDA approval to launch a Phase I clinical trial for a compound that can potentially treat anxiety, attention deficit disorder and other ...
<http://boston.bizjournals.com/boston/stories/2004/02/09/daily34.html?jst=b_ln_hl>

The compound is a proprietary dual action serotonin 1A (5HT1A) receptor agonist / sigma-1 antagonist intended to treat anxiety, attention deficit hyperactivity (ADHD) and other neuropsychiatric disorders.

Basically an SSRI.

From: http://news.biocompare.com/newsstory.asp?id=27098
Interesting drug company that came up with this drug - they design potential drugs by computer and then make and test them!